Oragenics, Inc. Announces Closing of Public Offering
2024年9月6日 - 5:30AM
Oragenics, Inc. (NYSE American: OGEN), a company focused on
developing unique, intranasal pharmaceuticals for the treatment of
neurological disorders, today announced the closing of its
previously announced offering of 3,078,378 shares of its common
stock and pre-funded warrants to purchase up to 5,028,206 shares of
common stock at an offering price of $0.55 per share and $0.549 per
pre-funded warrant. Immediately after the closing of the offering,
the Company has 8,659,071 shares of common stock outstanding and
pre-funded warrants to acquire up to 5,028,206 shares of common
stock outstanding. The exercise price of each pre-funded warrant is
$0.001.
The gross proceeds of the offering are
approximately $4.45 million before deducting placement agent fees
and other estimated offering expenses payable by the Company. The
Company intends to use the proceeds from the offering to fund
the continued development of its ONP-002 product candidate and for
general corporate purposes and working capital.
Dawson James Securities, Inc. acted as the sole
placement agent for the offering.
Shumaker, Loop & Kendrick, LLP, represented
the Company in connection with the offering, and ArentFox Schiff
LLP, Washington, DC, represented the placement agent.
The offering was made pursuant to a registration
statement on Form S-1 (File No. 333-281618), including a base
prospectus, filed with the U.S. Securities and Exchange Commission
(the “SEC”) on August 16, 2024, and declared effective on September
3, 2024.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy nor shall there be
any sale of these securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Oragenics
Oragenics is a development-stage biotechnology company focused
on nasal delivery of pharmaceutical medications in neurology and
fighting infectious diseases, including drug candidates for
treating mild traumatic brain injury (mTBI), also known as
concussion, and for treating Niemann Pick Disease Type C (NPC), as
well as proprietary powder formulation and an intranasal delivery
device. For more information, please
visit www.oragenics.com.
Forward-Looking Statements
This communication contains “forward-looking
statements” within the meaning of the safe harbor provisions of the
U.S. Private Securities Litigation Reform Act of 1995. These
forward-looking statements are based on management’s beliefs and
assumptions and information currently available. The words
“believe,” “expect,” “anticipate,” “intend,” “estimate,” “project”
and similar expressions that do not relate solely to historical
matters identify forward-looking statements. Investors should be
cautious in relying on forward-looking statements because they are
subject to a variety of risks, uncertainties, and other factors
that could cause actual results to differ materially from those
expressed in any such forward-looking statements. These factors
include, but are not limited to, those described in our Form 10-K
and other filings with the U.S. Securities and Exchange Commission.
All information set forth in this press release is as of the date
hereof. You should consider these factors in evaluating the
forward-looking statements included in this press release and not
place undue reliance on such statements. We do not assume any
obligation to publicly provide revisions or updates to any
forward-looking statements, whether as a result of new information,
future developments or otherwise, should circumstances change,
except as otherwise required by law.
Oragenics, Inc.Janet Huffman, Chief Financial
Officer813-286-7900jhuffman@oragenics.com
Investor Relations: Rich Cockrell 404.736.3838
achv@cg.capital
Oragenics (AMEX:OGEN)
過去 株価チャート
から 9 2024 まで 10 2024
Oragenics (AMEX:OGEN)
過去 株価チャート
から 10 2023 まで 10 2024